Products
Tepoditamab Biosimilar Bispecific Antibody (CLEC12A/CD371 × CD3) for Research
Pre-Made Tepoditamab biosimilar, Bispecific mAb, Anti-CLEC12A/CD371;CD3E Antibody: Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tepoditamab (formerly MCLA 117) a bispecific, human IgG antibody (with a silenced region), is being developed by Merus for the treatment of acute myeloid.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-563-1mg | 1mg | |
| GMP-Bios-ab-563-10mg | 10mg | |
| GMP-Bios-ab-563-100mg | 100mg | |
| GMP-Bios-ab-563-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tepoditamab biosimilar, Bispecific mAb, Anti-CLEC12A/CD371;CD3E Antibody: Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 therapeutic antibody |
| INN Name | Tepoditamab |
| Target | CD371;CD3E |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Genmab;Janssen Research & Development |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | na |
| Development Tech | na |
About target - CLEC12A
1. Protein C-type lectin domain family 12 member A
2. Gene CLEC12A
3. Organism Homo sapiens (Human)
Function
Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases.
